Analyzing the mechanism and experimental validation of Astilbe chinensis in the treatment of rheumatoid arthritis through network pharmacology

doi:10.5246/jcps.2024.03.020

Abstract

Abstract:

To unravel the active components and potential mechanisms of Astilbe chinensis in treating rheumatoid arthritis (RA), we employed a comprehensive strategy that combined network pharmacology and biological activity verification. Firstly, we identified the relevant compounds in A. chinensis from the literature, and RA-related targets were gathered through DisGeNET, GeneCards, and OMIM databases. Subsequently, compound-target and protein-protein interaction networks were constructed to predict the key compounds and promising protein targets of A. chinensis. Finally, these predictions were validated through in vitro anti-inflammatory activity experiments. A total of 29 potential active compounds and 117 intersecting pharmacological targets were identified. Among them, key active compounds included 3β,6β-dihydroxy olean-12-en-27-oic acid (astilbic acid), 3β-acetoxyolean-12-en-27-oic acid (3-acetyl oleanolic acid), 3β-hydroxyurs-12-en-27-oic acid, 4-O-galloylbergenin, and (+)/(-)-catechin. Key targets were identified as AKT1, MMP9, EGFR, CASP3, and HSP90AA1. GO enrichment analysis indicated that signal transduction, proteolysis, and negative regulation of the apoptotic process were closely associated with A. chinensis treatment in RA. KEGG pathway analysis indicated that pathways in cancer, osteoclast differentiation, and endocrine resistance might be crucial for A. chinensis intervention in RA. This finding suggested that multiple components in A. chinensis could regulate various signaling pathways and targets, playing preventive and therapeutic roles in RA. In vitro experiments demonstrated that A. chinensis extracts inhibited the secretion of inflammatory factors (NO, TNF-α, and IL-6) and significantly suppressed the expression of inducible nitric oxide synthase (iNOS), IL-6, and TNF-α mRNA in LPS-induced RAW 264.7 cells. Collectively, our findings not only established the theoretical basis for the efficacy of A. chinensis in treating RA but also provided a direction for subsequent research.

Key words: Astilbe chinensis, Rheumatoid arthritis, Network pharmacology, Anti-inflammatory activity

Supporting:

Ying Chen, Haixia Ying, Tingting Cai, Yunling Xu. Analyzing the mechanism and experimental validation of Astilbe chinensis in the treatment of rheumatoid arthritis through network pharmacology[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(3): 248-257.

Figures/Tables 6

References 20

[1]	Jang, S.; Kwon, E.J.; Lee, J.J. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int. J. Mol. Sci. 2022, 23, 905.
[2]	McInnes, I.B.; Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017, 389, 2328–2337.
[3]	Kronzer, V.L. Etiologies of rheumatoid arthritis: update on mucosal, genetic, and cellular pathogenesis. Curr. Rheumatol. Rep. 2021, 23, 21.
[4]	Dogra, S.; Khullar, G. Tumor necrosis factor-α antagonists: side effects and their management. Indian J. Dermatol. Venereol. Leprol. 2013, 79, 35–46.
[5]	Kedia, A.K.; Mohansundaram, K.; Goyal, M.; Ravindran, V. Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis. J. Royal Coll. Physicians Edinb. 2021, 51, 237–245.
[6]	Moon, T.C.; Lin, C.X.; Lee, J.S.; Kim, D.S.; Bae, K.; Son, K.H.; Kim, H.P.; Kang, S.S.; Son, J.K.; Chang, H.W. Antiinflammatory activity of astilbic acid from astilbe chinensis. Biol. Pharm. Bull. 2005, 28, 24–26.
[7]	Tu, J.; Sun, H.X.; Ye, Y.P. Immunomodulatory and antitumor activity of triterpenoid fractions from the rhizomes of Astilbe chinensis. J. Ethnopharmacol. 2008, 119, 266–271.
[8]	Hu, J.Y.; Yao, Z.; Xu, Y.Q.; Takaishi, Y.; Duan, H.Q. Triterpenes from Astilbe chinensis. J. Asian Nat. Prod. Res. 2009, 11, 236–242.
[9]	Xue, Y.; Xu, X.M.; Yan, J.F.; Deng, W.L.; Liao, X. Chemical constituents from Astilbe chinensis. J. Asian Nat. Prod. Res. 2011, 13, 188–191.
[10]	Kim, S.; Chen, J.; Cheng, T.J.; Gindulyte, A.; He, J.; He, S.Q.; Li, Q.L.; Shoemaker, B.A.; Thiessen, P.; Yu, B.; Zaslavsky, L.; Zhang, J.; Bolton, E.E. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2020, 49, D1388–D1395.
[11]	Liu, X.F.; Ouyang, S.S.; Yu, B.; Liu, Y.B.; Huang, K.; Gong, J.Y.; Zheng, S.Y.; Li, Z.H.; Li, H.L.; Jiang, H.L. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 2010, 38, W609–W614.
[12]	Morgat, A.; Lombardot, T.; Coudert, E.; Axelsen, K.; Neto, T.B.; Gehant, S.; Bansal, P.; Bolleman, J.; Gasteiger, E.; de Castro, E.; Baratin, D.; Pozzato, M.; Xenarios, I.; Poux, S.; Redaschi, N.; Bridge, A.; Consortium, T.U. Enzyme annotation in UniProtKB using rhea. Bioinformatics. 2020, 36, 1896–1901.
[13]	Piñero, J.; Ramírez-Anguita, J.M.; Saüch-Pitarch, J.; Ronzano, F.; Centeno, E.; Sanz, F.; Furlong, L.I. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020, 48, D845–D855.
[14]	Stelzer, G.; Rosen, N.; Plaschkes, I.; Zimmerman, S.; Twik, M.; Fishilevich, S.; Stein, T.I.; Nudel, R.; Lieder, I.; Mazor, Y.; Kaplan, S.; Dahary, D.; Warshawsky, D.; Guan-Golan, Y.; Kohn, A.; Rappaport, N.; Safran, M.; Lancet, D. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinformatics. 2016, 54, 1.30.1–1.30.33.
[15]	Amberger, J.S.; Bocchini, C.A.; Schiettecatte, F.; Scott, A.F.; Hamosh, A. OMIM.org: online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015, 43, 789–798.
[16]	Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; Jensen, L.J.; Mering, C.V. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, 607–613.
[17]	Xu, Y.L.; Zhang, Z.M.; He, J.L.; Chen, Z.X. Immune effects of macrophages in rheumatoid arthritis: a bibliometric analysis from 2000 to 2021. Front. Immunol. 2022, 13, 903771.
[18]	Weyand, C.M.; Klimiuk, P.A.; Goronzy, J.J. Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Springer Semin. Immunopathol. 1998, 20, 5–22.
[19]	Singh, J.A. Treatment guidelines in rheumatoid arthritis. Rheum. Dis. Clin. N Am. 2022, 48, 679–689.
[20]	Gil, T.Y.; Jin, B.R.; Hong, C.; Park, J.; An, H.J. Astilbe Chinensis ethanol extract suppresses inflammation in macrophages via NF-κB pathway. BMC Complement. Med. Ther. 2020, 20, 302.